Epidemiology of ductal carcinoma in situ

Journal of the National Cancer Institute - Monographs

Volumn , Issue 41, 2010, Pages 139-141

  Kerlikowske, Karla ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; ESTROGEN THERAPY; FAMILY HISTORY; GENE MUTATION; HUMAN; INTRADUCTAL CARCINOMA; LACTATION; MAMMOGRAPHY; MASTECTOMY; NULLIPARA; PARTIAL MASTECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; SMOKING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; BREAST TUMOR; CANCER REGISTRY; CLASSIFICATION; FEMALE; HORMONE SUBSTITUTION; INCIDENCE; MENOPAUSE; MIDDLE AGED; MORBIDITY; MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; RACE; REVIEW; RISK FACTOR; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CONTINENTAL POPULATION GROUPS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MAMMOGRAPHY; MASTECTOMY; MENOPAUSE; MIDDLE AGED; MORBIDITY; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SEER PROGRAM; UNITED STATES;

EID: 79952200754     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgq027     Document Type: Article

References (34)

1. White E, Lee CY, Kristal AR. Evaluation of the increase in breast cancer incidence in relation to mammography use. J Natl Cancer Inst. 1990;82(19):1546-1552.
2. Ernster V, Ballard-Barbash R, Barlow W, et al. Detection of DCIS in women undergoing screening mammography. J Natl Cancer Inst. 2002;94(20):1546-1554.
3. Kerlikowske K, Grady D, Barclay J, Sickles EA, Eaton A, Ernster V. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA. 1993;270(20):2444-2450.
4. May D, Lee N, Richardson L, Giustozzi A, Bobo J. Mammography and breast cancer detection by race and Hispanic ethnicity: results from a national program (United States). Cancer Causes Control. 2000;11(8):697-705.
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
6. Horner M, Ries L, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009. http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER Web site, September 1, 2009. Accessed August 30, 2010.
7. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson IC. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275(12):913-918.
8. Li C, Daling J, Malone K. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev. 2005;14(4):1008-1011.
9. Kerlikowske K, Miglioretti D, Buist D, Walker R, Carney P. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007;99(17):1335-1339.
10. Randolph W, Goodwin J, Mahnken J, Freeman J. Regular mammography use is associated with elimination of age-related disparities in size and stage of breast cancer at diagnosis. Ann Intern Med. 2002;137(10):783-790.
11. Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M. Trends in breast cancer by race and ethnicity. CA Cancer J Clin. 2003;53(6):342-355.
12. Kerlikowske K, Creasman J, Leung J, Smith-Bindman R, Ernster V. Differences in screening mammography outcomes among white and Asian women. Arch Intern Med. 2005;165(16):1862-1868.
13. Claus E, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst. 2001;93(23):1811-1817.
14. Kerlikowske K, Barclay J, Grady D, Sickles E, Ernster V. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst. 1997;89(1):77-82.
15. Reinier K, Vacek P, Geller B. Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. Breast Cancer Res Treat. 2007;103(3):343-348.
16. Gill JK, Maskarinec G, Pagano I, Kolonel LN. The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort. Breast Cancer Res. 2006;8(3):R30.
17. Trentham-Dietz A, Newcomb P, Storer B, Remington P. Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2000;9(7):697-703.
18. Kerlikowske K, Walker R, Miglioretti D, Desai A, Ballard-Barbash R, Buist D. Obesity, mammography use and accuracy, and advanced breast cancer risk. J Natl Cancer Inst. 2008;100(23):1724-1733.
19. Wohlfahrt J, Rank F, Kroman N, Melbye M. A comparison of reproductive risk factors for CIS lesions and invasive breast cancer. Int J Cancer. 2004;108(5):750-753.
20. Kerlikowske K, Miglioretti D, Ballard-Barbash R, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol. 2003;21(23):4314-4321.
21. MacKenzie T, Titus-Ernstoff L, Vacek P, et al. Breast density in relation to risk of ductal carcinoma in situ of the breast in women undergoing screening mammography. Cancer Causes Control. 2007;18(9):939-945.
22. Patel AV, Press MF, Meeske K, Calle EE, Bernstein L. Lifetime recreational exercise activity and risk of breast carcinoma in situ. Cancer. 2003;98(10):2161-2169.
23. Claus E, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 2005;294(8):964-969.
24. Syrjakoski K, Vahteristo P, Eerola H, et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst. 2000;92(18):1529-1531.
25. Phillips LS, Millikan RC, Schroeder JC, Barnholtz-Sloan JS, Levine BJ. Reproductive and hormonal risk factors for ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1507-1514.
26. Venkatesan A, Chu P, Kerlikowske K, Sickles E, Smith-Bindman R. Positive predictive value of specific mammographic findings according to reader and patient variables. Radiology. 2009;250(3):648-657.
27. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96(6):443-448.
28. Kumar AS, Bhatia V, Henderson IC. Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective. Breast Cancer Res. 2005;7(6):271-275.
29. Jackson LC, Camacho F, Levine EA, Anderson RT, Stewart JHIV. Patterns of care analysis among women with ductal carcinoma in situ in North Carolina. Am J Surg. 2008;195(2):164-169.
30. Sumner WE, Koniaris LG, Snell SE, et al. Results of 23,810 cases of ductal carcinoma-in-situ. Ann Surg Oncol. 2007;14(5):1638-1643.
31. Tuttle TJ, Habermann EB, Arrington A, Abraham A, Morris TJ, Virnig BA. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27(9):1362-1367.
32. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based SEER Program. Arch Intern Med. 2000;160(7):953-958.
33. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from national surgical adjuvant breast and bowel project B-17. J Clin Oncol. 1998;169(2):441-452.
34. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003;95(22):1692-1702.